Business Context and Reporting Period
This Form 6-K filing by Dr. Reddy's Laboratories Limited covers the period ending July 31, 2009. It primarily disseminates three press releases: the filing of the Annual Report on Form 20-F for the fiscal year ended March 31, 2009; the unaudited financial results for the first quarter of fiscal year 2010 (Q1 FY10) ended June 30, 2009; and the launch of a new product in India. The company operates as a global pharmaceutical firm with core businesses in Pharmaceutical Services & Active Ingredients (PSAI), Global Generics, and Proprietary Products.
Key Financial Metrics (Q1 FY10 vs. Q1 FY09)
| Metric | Q1 FY10 (Rs. Million) | Q1 FY10 (USD Million) | Q1 FY09 (Rs. Million) | Q1 FY09 (USD Million) | YoY Growth |
|---|---|---|---|---|---|
| Revenue | 18,189 | 381 | 15,038 | 315 | 21% |
| EBITDA | 4,364 | 91 | 2,300 | 48 | 90% |
| Profit After Tax (PAT) | 2,445 | 51 | 1,111 | 23 | 120% |
| Adjusted PAT | 2,800 | 60 | 1,300 | 28 | 116% |
| EPS (Diluted) | 14.5 | 0.3 | 6.6 | 0.1 | 119% |
| Gross Margin | 56% | - | 50% | - | +600 bps |
| Operating Income | 3,295 | 69 | 1,118 | 23 | 195% |
Balance Sheet Highlights (as of June 30, 2009):
- Cash and Cash Equivalents: Rs. 6,184 million ($130 million).
- Total Loans and Borrowings: Rs. 16,108 million ($337 million), down from Rs. 19,701 million as of March 31, 2009.
- Equity: Rs. 44,832 million ($939 million).
Material Changes and Segment Performance
The 21% revenue growth was largely driven by the launch of sumatriptan and strong performance in North America and India. Excluding sumatriptan, organic year-over-year growth was 7%.
- Global Generics: Revenue grew 27% to Rs. 13.0 billion. North America revenue surged to Rs. 6.0 billion (up from Rs. 2.8 billion), driven by high volume growth and sumatriptan. Europe revenue declined 30% to Rs. 2.1 billion, primarily due to destocking at the betapharm subsidiary.
- Pharmaceutical Services & Active Ingredients (PSAI): Revenue increased 6% to Rs. 4.9 billion, driven by Europe and Rest of World regions, as well as rupee depreciation benefits.
- India: Revenue grew 9% to Rs. 2.4 billion, supported by key brands including Omez, Nise, and Razo.
- Cost Structure: Gross profit margins expanded to 56% from 50% due to higher margins on sumatriptan. SG&A expenses rose 17% to Rs. 5.9 billion; however, excluding one-time exit costs for the betapharm sales force restructuring and Atlanta facility closure, SG&A growth was only 6%.
Guidance, Outlook, and Risks
Operational Highlights: The company launched 24 new generic products, filed 22 new generic product registrations, and filed 4 DMFs globally during the quarter. The order book for active ingredients increased 27% sequentially.
Restructuring: The sales force at the betapharm subsidiary was restructured, reducing headcount from 110 to approximately 50 as of June 2009.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers regarding economic conditions, market acceptance, and regulatory risks. Specific financial impacts noted include a Rs. 515 million provision for damages in Q1 FY09 related to the olanzapine patent in Germany, which is not present in the current quarter. The company also noted a net forex loss of Rs. 84 million in Q1 FY10 compared to a gain in the prior year.
Key Facts for Investor Verification
- Sumatriptan Impact: Verify the sustainability of revenue growth excluding the one-time or launch-driven impact of sumatriptan, which accounts for a significant portion of the 21% top-line growth.
- Europe Destocking: Monitor the recovery of the betapharm subsidiary in Europe, which saw a 36% revenue decline due to market destocking and subsequent sales force restructuring.
- Patent Litigation: Confirm the status of the olanzapine patent litigation in Germany, which resulted in a significant provision in the prior year.
- ANDA Pipeline: Review the progress of the 67 pending ANDAs (including 28 Paragraph IVs) at the USFDA, which represent potential future revenue streams.
- Currency Exposure: Assess the impact of currency fluctuations, as the company noted a shift from a forex gain in Q1 FY09 to a forex loss in Q1 FY10.